FDA facility acquisition data room: records that answer better questions

A useful quality data room helps a reviewer reconstruct decisions. A large folder of certificates and signed summaries may look complete while leaving the underlying question unanswered.

Index by operation and decision

Begin with a map of legal entities, locations, product families, and activities. Link each important quality decision to the record supporting it. An index should make scope, record version, date, owner, and known gaps visible.

Keep original evidence connected

For a laboratory result, connect the reported conclusion with sample identity, method version, original observations, calculations, review, and any investigation. For equipment, connect intended use with qualification evidence, maintenance, calibration, changes, and current status. Choose trails relevant to the actual operation; not every example applies to every regulated business.

Preserve exceptions

Maintain a separate unresolved-issues register. State whether an item is missing, withheld pending permission, awaiting retrieval, or genuinely unavailable. Do not turn “not provided” into “does not exist,” or treat a seller’s explanation as independently verified evidence.

Control access and follow-up

Agree authorized access, confidentiality, and handling of sensitive records before transfer. Use appropriate redaction and a secure review process. Identify who can answer follow-up questions and how the buyer will obtain continued access to records after closing.

This is an independent diligence organization method. It is not an FDA-required data-room format or a certification of compliance. FDA’s CGMP topic directory can help identify relevant drug-quality areas; applicability to other product categories must be assessed separately.

Continue the facility planning cluster

New facility planning · Buying a regulated business · Quality data room · Startup readiness · Contract laboratory acquisition

Request a scoped facility review or customized team training.